A new study by Queen's University researchers found that one-third of Canadian adults experience a sore throat, cold or flu each month, with women more likely to self-treat and consult doctors. The study estimated annual economic costs of colds in Canada at $40 billion, highlighting the need for preventative measures.
A landmark trial will recruit 500 children to test a patented extract of North American ginseng called COLD FX, with 60% expected to develop an infection and be eligible for the study. The trial aims to provide safe and effective treatment options for parents struggling with pediatric cold and flu medicines.
A landmark trial is underway to assess whether COLD-FX reduces infections in chronic lymphocytic leukemia patients, who are vulnerable to respiratory infections due to weakened immune systems. The study aims to evaluate the effectiveness of COLD-FX in preventing and treating viral respiratory infections.
A new study found that vaccinated seniors who took COLD-FX had a one-third lower chance of getting a 'Jackson' cold or flu. The supplement, a unique extract of North American ginseng, also provided added protection on top of the flu shot's benefit.
A Canadian study involving children and a botanical extract (COLD-fX) shows promise for its future development as a cold and flu remedy. The study, published in Pediatrics, found that acute three-day doses of COLD-fX were well-tolerated with no serious adverse events.